Cancer rates in teens and early 20s rising

March 01, 2004

London, UK: A new analysis of cancer figures for England[1] shows that the overall incidence among teenagers and young adults is rising, with the biggest increase among 20 to 24-year-olds, particularly in lymphoma, melanoma and germ cell tumours, including testicular germ cell tumours.

A news briefing at Teenage Cancer Trust's Third International Conference on Adolescent Cancer today (Monday 1 March) was told that although cancer is still rare in this age group - around 1,500 cases a year in England - it is the leading cause of death after accidents.

Professor Jill Birch, from the University of Manchester, [NB:see note at end of this release] who analysed data for 13 to 24-year-olds between 1979 and 2000, said that the overall rate had risen from 15.4 to 19.8 per 100,000 over the 21 year period 1979-2000. This amounts to an average increase of 1.2% per year.

Different cancers dominated at different ages. Among 13 and14-year-olds, leukaemia is the most common accounting for over 22% of cancers, followed by lymphoma (nearly 21%) and malignant brain tumours (18%). By age 15-19 lymphoma dominates (27%) with leukaemia second (15%) followed by carcinomas and malignant brain tumours (around 11% each). Lymphoma also dominated in 20 to 24-year olds with carcinomas second (21%) and germ cell tumours third (17%).

Much less is known about the causes and risk factors for adolescent and young adult cancer than for cancer in older adults.

Professor Birch, who is Cancer Research UK Professorial Research Fellow at Manchester University, said: "The early age of onset and lack of opportunity for chronic exposure to environmental factors suggests that genetic susceptibility may be important. Highly penetrant genes or mutations probably only account for a small proportion of cases. What is more likely is that cancer develops as a result of exposure to a risk factor in a genetically susceptible individual."

She said that the increasing incidence of certain cancers over time would be consistent with environmental (exogenous) risk factors, which are becoming more frequent or occurring at increasing levels. Alternatively, lifestyle changes in recent years may also be contributing. For example, melanoma rates (linked to sun exposure) had almost doubled over 21 years and in the 20-24 year age group now accounted for one in 10 of all cancers.

"Exposure of a young child or fetus to environmental carcinogens during periods of rapid growth and development might lead to higher cancer risks in young adults than adult exposure at similar doses would to the risk of cancer in later life."

Infection in early life could be important in lymphoma with risks varying according to the individual's HLA (histocompatability) system. Likewise, individuals' genetic make up may make them susceptible to the ability of viruses to trigger cancer. Passive smoking may be a factor in some cancers, but exposure that happens before birth or in infancy may target different organs than those affected by exposure in later life. Again, the genetic make up of mother and fetus is likely to affect the level of risk.

Professor Birch said that good quality data on patterns and trends in cancer incidence were essential for researching and understanding causes and she called for a specialised system of cancer registration in this age group.

"We understand patterns of childhood cancer fairly well because there are specialised registries internationally. But childhood classifications don't work for adolescents and young adults because many of the childhood cancers are not seen in adolescents. Adult data are presented by cancer site but that is not suitable for teenagers and young adults either. That's an important reason why we don't understand nearly so much about this age group.

"What we need is a classification that is tailored to the 13 to 24-year-olds with biologically similar cancers classified together, and diagnostic categories that allow maximum flexibility in analyses. A standard classification that is accepted internationally will ensure that results from different registries are comparable."

She concluded: "This would allow us to analyse by diagnosis, age, sex, geographical variations and to undertake international comparisons. Studies of familial patterns will also be important. Then we would have a proper basis for detailed molecular epidemiological studies that could really help us to identify the causes of the cancers that are affecting our young people."
-end-
[1] Data provided by National Cancer Intelligence Centre, ONS. Study included 32,000 cancers diagnosed in young persons aged 13-24 years between 1979 and 2000.

Note: Professor Jill Birch was to have given the presentation on incidence and aetiology to the conference at 09.00 Tuesday 2 March and to the news briefing at 10.30am Monday 1 March, but has had to withdraw for personal reasons. Professor Tim Eden, University of Manchester and Christie Hospital, Manchester, will now make the presentation to the conference and Mr Charles Stiller, senior research fellow, Childhood Cancer Research Group, Oxford University, will talk about incidence and aetiology at the news briefing.

Contacts:
Margaret Willson: conference media consultant:
44-153-677-2181
Mobile: 44-797-385-3347 Home: 44-153-677-0851
Email: m.willson@mwcommunications.org.uk

Lucy Shure: TCT head of campaigns and media:
44-207-387-1000
Mobile: 44-793-136-2729
Email: lucys@teencancer.bdx.co.uk

Conference press office [From 9am-6pm GMT Monday 1 March and from 9am-1pm GMT Tuesday 2 March] Tel: 44-207-224-3137.

Teenage Cancer Trust

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.